Exchange: NASDAQ·Updated 12:03 PM EDT
News
all
press releases
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
More News
Transcript: Arvinas Q2 2026 Earnings Conference Call
Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earningsread more...
Benzinga
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +1,175.00% and +562.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.
Zacks
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Full Transcript: Arvinas Q1 2026 Earnings Call
read more...
Benzinga
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.read more...
Benzinga
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?
Rigel Pharmaceuticals signed a global licensing deal with Arvinas and Pfizer for an advanced breast cancer treatment.
Stocktwits
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +5.01% and -0.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.